Mesoblast Limited MESO announced that the FDA has approved Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in children aged two months ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback